UBM Stock Overview
A healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Ulisse Biomed S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.76 |
| 52 Week High | €1.90 |
| 52 Week Low | €0.72 |
| Beta | 0.63 |
| 1 Month Change | -6.67% |
| 3 Month Change | -24.40% |
| 1 Year Change | -54.32% |
| 3 Year Change | -77.30% |
| 5 Year Change | n/a |
| Change since IPO | -76.53% |
Recent News & Updates
Shareholder Returns
| UBM | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | -7.6% | 0.5% | 1.3% |
| 1Y | -54.3% | 9.8% | 9.7% |
Return vs Industry: UBM underperformed the Italian Biotechs industry which returned 11% over the past year.
Return vs Market: UBM underperformed the Italian Market which returned 9.5% over the past year.
Price Volatility
| UBM volatility | |
|---|---|
| UBM Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IT Market | 7.9% |
| 10% least volatile stocks in IT Market | 2.6% |
Stable Share Price: UBM has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: UBM's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 8 | Nicola Basile | www.ulissebiomed.com |
Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases and HPV.
Ulisse Biomed S.p.A. Fundamentals Summary
| UBM fundamental statistics | |
|---|---|
| Market cap | €16.66m |
| Earnings (TTM) | -€6.97m |
| Revenue (TTM) | €420.92k |
39.6x
P/S Ratio-2.4x
P/E RatioIs UBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UBM income statement (TTM) | |
|---|---|
| Revenue | €420.92k |
| Cost of Revenue | €1.87m |
| Gross Profit | -€1.45m |
| Other Expenses | €5.52m |
| Earnings | -€6.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | -343.30% |
| Net Profit Margin | -1,655.06% |
| Debt/Equity Ratio | 1.8% |
How did UBM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 05:47 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ulisse Biomed S.p.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marco Greco | ValueTrack |
| Valentina Romitelli | ValueTrack |